Company Reports

Recent Updates

All Reports

Company Report

Demant is a Danish healthcare group focused on hearing aids. It operates as a vertically integrated business across three divisions: hearing aids, hearing care, and diagnostics.
Stock Analyst Note

Demant reported 2% organic sales growth in 2025, slightly above company-compiled consensus. Organic growth accelerated to 5% in the fourth quarter. Adjusted EBIT was in line with consensus at DKK 3,960 million. Markets reacted negatively, with the share price down 10%.
Company Report

Demant benefits from favourable trends, including an ageing population, increasing noise pollution, fairly low penetration rates in the developed world, and virtually untapped patient populations in emerging markets such as China. Demant's broad product offerings should allow the company to capitalize on these trends, while its strong brand and superior technological know-how should yield market share gains. Following the sale of its implant business and the upcoming disposition of the communications segment, Demant is in a better position to focus its efforts and maintain its top-tier positioning in the market.
Company Report

Demant benefits from favourable trends, including an ageing population, increasing noise pollution, fairly low penetration rates in the developed world, and virtually untapped patient populations in emerging markets such as China. Demant's broad product offerings should allow the company to capitalize on these trends, while its strong brand and superior technological know-how should yield market share gains. Following the sale of its implant business and the upcoming disposition of the communications segment, Demant is in a better position to focus its efforts and maintain its top-tier positioning in the market.

Sponsor Center